Sercarz J A, Mark R J, Nasri S, Wang M B, Tran L M
Division of Head and Neck Surgery, University of California, Los Angeles School of Medicine 90024, USA.
Int J Pediatr Otorhinolaryngol. 1995 Jan;31(1):15-22. doi: 10.1016/0165-5876(94)01062-3.
The optimal treatment for most patients with pediatric rhabdomyosarcoma (RMS) of the head and neck has been shown to be a combination of surgery, chemotherapy and radiation therapy. A retrospective review of patients seen at our institution is presented to analyze the impact of multimodality treatment on survival in 32 pediatric RMS patients. Sixty-five percent (21/32) of the patients were disease free at the most recent follow-up. The 5 year disease free survival was 57% (17/30). Combined modality treatment in 25 patients consisting of chemotherapy, radiation therapy and surgical resection (in 5 patients) rendered 18 (72%) patients free of disease. Only 1 of 7 (14%) patients who underwent surgery alone as primary management was cured. Two of these 7 patients were salvaged, both with combined modality treatment. The Intergroup Rhabdomyosarcoma Study (IRS) protocols have resulted in increased survival in pediatric patients with RMS of the head and neck. Our results reflect the significant improvement since the IRS study was completed.
多数头颈部小儿横纹肌肉瘤（RMS）患者的最佳治疗方案已被证明是手术、化疗和放疗相结合。本文对我院收治的患者进行回顾性分析，以探讨多模式治疗对32例小儿RMS患者生存情况的影响。在最近一次随访时，65%（21/32）的患者无疾病。5年无病生存率为57%（17/30）。25例患者接受了包括化疗、放疗和手术切除（5例）在内的联合治疗，其中18例（72%）患者无疾病。仅1例（14%）以单纯手术作为主要治疗手段的患者治愈。这7例患者中有2例经联合治疗后病情得到挽救。横纹肌肉瘤协作组（IRS）的方案提高了小儿头颈部RMS患者的生存率。我们的结果反映了自IRS研究完成以来的显著改善。
